MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
23.32
-0.98
-4.03%
After Hours: 23.32 0 0.00% 16:10 02/10 EST
OPEN
23.84
PREV CLOSE
24.30
HIGH
24.09
LOW
22.98
VOLUME
656.07K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.42B
P/E (TTM)
-5.6617
1D
5D
1M
3M
1Y
5Y
1D
Kodiak Sciences Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 19h ago
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $38 Price Target
Benzinga · 19h ago
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Protara Therapeutics (TARA) and Kodiak Sciences (KOD)
TipRanks · 20h ago
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX)
TipRanks · 1d ago
Weekly Report: what happened at KOD last week (0202-0206)?
Weekly Report · 1d ago
Kodiak Sciences präsentiert erfolgreiche Phase-1b-Studienergebnisse für KSI-101 bei Makulaödem durch Entzündung
Reuters · 6d ago
Kodiak Sciences Reports Positive Phase 1b Results for KSI-101 in Macular Edema Secondary to Inflammation
Reuters · 6d ago
Kodiak Sciences: A Stellar Move
Seeking Alpha · 02/03 12:48
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.